Breast Cancer
Conditions
Brief summary
Age may pertain to different tumor genotype characteristics which may interfere with treatment efficacy and prognosis. The investigators investigated the distribution and prognostic effect of mutations (mut) and tumor infiltrating lymphocyte (TILs) in young and elderly early breast cancer patients (pts).
Interventions
GENETICCorellation of Mutations, TILs and Age in Breast Cancer
Sponsors
Hellenic Cooperative Oncology Group
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* women with early breast cancer \<35 years old or \>65 years old
Exclusion criteria
* NA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the prevalence of gene mutations in women <=35 years old with early breast cancer. | Up to 13 years |
| Assessment of the prevalence of gene mutations in women >65years old with early breast cancer. | Up to 13 years |
| Evaluation of Tumor Infiltrating Lymphocytes (TILs) density using descriptive statistics in women <=35 years old with early breast cancer. | Up to 13 years |
| Evaluation of Tumor Infiltrating Lymphocytes (TILs) density using descriptive statistics in women >65 years old with early breast cancer. | Up to 13 years |
| Evaluation of the prognostic effect of gene mutations and Tumor Infiltrating Lymphocytes with respect to Overall Survival in women <=35 years old with early breast cancer | Up to 13 years |
| Evaluation of the prognostic effect of gene mutations and Tumor Infiltrating Lymphocytes with respect to Overall Survival in women >65 years old with early breast cancer. | Up to 13 years |
Outcome results
None listed